Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms

The U.S. formulations revenue increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; Europe formulations revenue driven by robust performance across all key market.

This story is aggregated from The Hindu - Business. We display only the headline and a short executive summary with attribution to the original source.